⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249696 | 0.88 | — | — | |
| SCHEMBL60542 | 0.78 | — | — | |
| SCHEMBL21807338 | 0.78 | — | — | |
| Ammonia Solution, Strong SCHEMBL27931519 | 0.76 | HSP90AA1 (0.42) | — | |
| SCHEMBL217162 | 0.75 | HSP90AA1 (0.34) | — | |
| SCHEMBL26916031 | 0.75 | PKM (0.47) | — | |
| SCHEMBL1255495 | 0.75 | TSHR (0.36) | — | |
| SCHEMBL136059 | 0.73 | — | — | |
| SCHEMBL6840184 | 0.73 | — | — | |
| SCHEMBL5257325 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112823157-B | Spirochroman derivatives | 吉瑞工厂 | 2024-08-09 | — | — | CN | disclosed |
| EP-4400172-A2 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20240190870-A1 | FGFR3 INHIBITOR COMPOUNDS | LOXO ONCOLOGY, INC. | 2024-06-13 | — | — | US | disclosed |
| US-20240190869-A1 | 5,7-DIHYDRO-PYRROLO-PYRIDINE DERIVATIVES | PFIZER (US) | 2024-06-13 | — | — | US | disclosed |
| WO-2024108009-A1 | DYRK/CLK PROTACS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-4370504-A1 | PROCESS AND INTERMEDIATES FOR PREPARING BARICITINIB | Incyte Corporation (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-4346898-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4036088-B1 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | INCYTE HOLDINGS CORP (US) | 2024-04-03 | — | — | EP | disclosed |
| US-11905284-B2 | 5,7-dihydro-pyrrolo-pyridine derivatives | PFIZER INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240050577-A1 | CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF | RISEN (SHANGHAI) PHARMA ENG CO., LTD. (CN) | 2024-02-15 | — | — | US | disclosed |
| EP-2032566-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-03-11 | — | — | EP | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| EP-1954277-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | Vertex Pharmceuticals Incorporated (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1934174-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008020206-A2 | FUSED THIOPHENE DERIVATIVES AS MEK INHIBITORS | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | WO | disclosed |
| WO-2007143823-A1 | AZETIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007056221-A2 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007044515-A1 | AZETIDINES AS MEK INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2002012187-A1 | NOVEL PHENYLHETEROAZETIDINES, USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |